Patents by Inventor Marc Werner Andersen

Marc Werner Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formamide compounds as therapeutic agents
    Patent number: 6329400
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: December 11, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, Dulce Garrido Bubacz, Joseph Howing Chan, David John Cowan, Michael David Gaul, Daryl Lynn McDougald, David Lee Musso, Michael Howard Rabinowitz, Jennifer Badiang Stanford, Robert William Wiethe
  • Formamide compounds as therapeutic agents
    Patent number: 6191150
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: February 20, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, Dulce Garrido Bubacz, Joseph Howing Chan, David John Cowan, Michael David Gaul, Daryl Lynn McDougald, David Lee Musso, Michael Howard Rabinowitz, Jennifer Badiang Stanford, Robert William Wiethe
  • Formamides as therapeutic agents
    Patent number: 6172064
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof. Also described are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: January 9, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, David John Cowan, David Norman Deaton, Scott Howard Dickerson, David Harold Drewry, Michael David Gaul, Michael Joseph Luzzio, Brian Edward Marron, Michael Howard Rabinowitz
  • 2-amino-5,6-dichlorobenzimidazole derivatives having antiviral activity
    Patent number: 5998398
    Abstract: The present invention relates to benzimidazole derivatives of formula (I) wherein: R.sup.1 represents H, C.sub.1-4 alkyl, C.sub.3-5 cycloalkyl; R.sup.2 represents H, C.sub.1-4 alkyl; or R.sup.1 and R.sup.2 together form with the nitrogen a 4 or 5 membered heterocyclic ring; R.sup.3 represents BR.sup.4 or R.sup.4 wherein B represents a bridging group --C(O)NH--, --C(O)NC.sub.1-4 alkyl-, or C(O)O-- and R.sup.4 represents H, C.sub.1-4 alkyl, C.sub.2-6 alkenyl or halo (preferably fluoro); and each n is an integer independently selected from 0, 1, or 2 (preferably 0 or 1); and geometric isomers or mixtures thereof; and physiologically functional derivatives thereof, and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to their preparation and pharmaceutical formulations containing them.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: December 7, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Mary Daluge, Marc Werner Andersen